Founded in 2019, BioSotop is dedicated to developing, producing, selling and serving stable isotope-labeled drugs.
BioSotop (Chinese:鼎邦生物) raised tens of millions of CNY in angle round from Yanghe Investment. The fund will be used for R&D investment and technological innovation.
The drugs under development by the startup are mainly labeled by stable isotopes such as 2H, 10B, 13C, 18O, etc. Among them, 2H (deuterium)-labeled drug is a medical imaging drug that can be applied to clinical magnetic resonance metabolic imaging. It could be used not only in vivo quantitative determination but also in early screening and diagnosis of cancer (metabolic tumors like liver cancer and glioma) and neurodegenerative diseases. BioSotop also has drug synthesis and drug analysis laboratories equipped with high-end instruments such as HPLC, GC/MS, UPLC/MS, etc.
The field BioSotop focuses on is DMI (deuterium metabolic imaging) which is a new generation of non-invasive ultra-high field magnetic resonance imaging. Some of its key products have completed preclinical studies and are ready to enter the IND stage. Besides new drug development, BioSotop conducts businesses like molecular magnetic resonance imaging CRO, achieving initial commercialization.
BioSotop's founder, Xiaojun Yang, once studied nuclear physics at the University of Science and Technology of China and has entrepreneurial experience and resources.
According to data from Frost&Sullivan and Northeast Securities, from 2014 to 2018, China's market size of isotope application in medicine expanded from CNY 3.25 billion to 5.13 billion, with a compound annual growth rate of 12.1%. It is expected that the following years will see further growth in the size of this market.
BioSotop's competitors include Shunbang (Chinese:绍兴舜邦医药科技), Beita Pharmatech (Chinese:无锡贝塔医药科技), SustGreen Tech(Chinese:昊绿生物科技).